4 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell MalignanciesB-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasmActive, not recruitingPhase 12026-05-07NCT06014762
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerInsulin Resistance, Neoplasms by Site, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, glucose metabolism disease, hyperglycemia, hyperinsulinism, metabolic disease, neoplasm, skin disorderRecruitingPhase 1 / Phase 22026-04-22NCT05455619
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodDisease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmActive, not recruitingPhase 1 / Phase 22026-04-01NCT03793478
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C MutationActive, not recruitingPhase 12025-10-22NCT04185883